Corcept Therapeutics Inc (CORT): Shareholders' Equity
$647.80M
As of 2025-12-31
$705.78M
As of 2026-06-30
+8.9%
3-year compound annual growth
+4.4%
5-year compound annual growth
+42.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $647.80M | -4.7% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $679.59M | +34.1% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $506.70M | +1.0% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $501.84M | +33.5% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $375.81M | -28.2% | 2024-02-15, Balance as of period end |
| 2020-12-31 | $523.34M | +41.0% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $371.18M | +34.5% | 2022-02-15, Balance as of period end |
| 2018-12-31 | $275.88M | +44.5% | 2021-02-23, Balance as of period end |
| 2017-12-31 | $190.97M | +361.5% | 2020-02-24, Balance as of period end |
| 2016-12-31 | $41.38M | +123.7% | 2019-02-26, Balance as of period end |
| 2015-12-31 | $18.50M | n/m | 2018-02-28, Balance as of period end |
| 2014-12-31 | -$3.39M | n/m | 2017-03-06, Balance as of period end |
| 2013-12-31 | $21.02M | -66.0% | 2016-03-10, Balance as of period end |
| 2012-12-31 | $61.78M | +77.5% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $34.81M | +63.8% | 2014-03-14, Balance as of period end |
| 2010-12-31 | $21.24M | -3.8% | 2013-03-15, Balance as of period end |
| 2009-12-31 | $22.09M | +30.7% | 2012-03-13, Balance as of period end |
| 2008-12-31 | $16.91M | +14.7% | 2012-03-13, Balance as of period end |
| 2007-12-31 | $14.73M | +131.7% | 2012-03-13, Balance as of period end |
| 2006-12-31 | $6.36M | -76.1% | 2012-03-13, Balance as of period end |
| 2005-12-31 | $26.59M | -42.1% | 2012-03-13, Balance as of period end |
| 2004-12-31 | $45.95M | n/m | 2012-03-13, Balance as of period end |
| 2003-12-31 | -$31.47M | n/m | 2012-03-13, Balance as of period end |
| 2002-12-31 | -$21.94M | n/m | 2012-03-13, Balance as of period end |
| 2001-12-31 | -$7.54M | n/m | 2012-03-13, Balance as of period end |
| 2000-12-31 | -$2.00M | n/m | 2012-03-13, Balance as of period end |
| 1999-12-31 | -$244.0K | n/a | 2012-03-13, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $522.60M | +8.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $301.68M | +31.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.06B | +2.5% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $503.42M | +163.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$80.00M | n/m |
Compare CORT, EBS, COLL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗